Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

See Locations Near You

Summary

This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.

View Full Description

Full Description

Treatment Plan:

7.5 Gy x 10 daily fractions delivered with volumetric modulated arc therapy (VMAT) or regular intensity-modulated radiation therapy (IMRT).

Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal planning target volume (PTV) coverage is achieved; but the 7.5 Gy x 10 daily fractions schedule is preferred.
All doses are prescribed to the tumor periphery.

For this protocol, patients will be followed only up to 2 years post radiation therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Non-Small Cell Lung Cancer
T2N0M0 or T3(PL3)N0M0 or Locally recurrent ≤ 7 cm
Surgically inoperable
ECOG Performance 0-2

Exclusion Criteria:

Pacemaker on the same side of the tumor
Pregnant
Infection that requires IV antibiotics
Concomitant or adjuvant anti-neoplastic chemotherapy

Study is for people with:

Lung Cancer

Estimated Enrollment:

3

Study ID:

NCT02262000

Recruitment Status:

Terminated

Sponsor:

West Virginia University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

West Virginia University Hospitals Mary Babb Randolph Cancer Center
Morgantown West Virginia, 26506, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

3

Study ID:

NCT02262000

Recruitment Status:

Terminated

Sponsor:


West Virginia University

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider